{"id":1618,"date":"2026-05-08T13:53:38","date_gmt":"2026-05-08T11:53:38","guid":{"rendered":"https:\/\/www.sunrockbiopharma.com\/ccr9\/"},"modified":"2026-06-23T11:15:54","modified_gmt":"2026-06-23T09:15:54","slug":"ccr9","status":"publish","type":"page","link":"https:\/\/www.sunrockbiopharma.com\/es\/ccr9\/","title":{"rendered":"CCR9"},"content":{"rendered":"

[vc_row][vc_column css_animation=\u00bbfadeInUp\u00bb el_class=\u00bbbox-shadow\u00bb][vc_column_text]<\/p>\n

CCR9 como diana terap\u00e9utica<\/h2>\n

[\/vc_column_text][vc_column_text]<\/p>\n

El receptor de quimiocinas 9 (CCR9<\/strong>) es un receptor acoplado a prote\u00edna G implicado en la regulaci\u00f3n del tr\u00e1fico de c\u00e9lulas inmunitarias, dirigiendo especialmente el homing de linfocitos hacia el tracto intestinal mediante su interacci\u00f3n con el ligando CCL25<\/strong>. Aunque su expresi\u00f3n fisiol\u00f3gica est\u00e1 restringida principalmente al timo y al intestino delgado, la activaci\u00f3n aberrante del eje CCR9\/CCL25<\/strong> se ha relacionado con m\u00faltiples enfermedades.<\/p>\n

En enfermedades inmunomediadas como la enfermedad inflamatoria intestinal (EII)<\/strong>, CCR9 favorece el reclutamiento de linfocitos patog\u00e9nicos hacia los tejidos intestinales inflamados, contribuyendo a la inflamaci\u00f3n cr\u00f3nica y la fibrosis. Paralelamente, CCR9 se encuentra frecuentemente sobreexpresado en tumores s\u00f3lidos y hematol\u00f3gicos, donde promueve la progresi\u00f3n tumoral, la diseminaci\u00f3n metast\u00e1sica y la resistencia a los tratamientos.<\/p>\n

En conjunto, estas funciones convierten a CCR9 en una diana terap\u00e9utica de gran inter\u00e9s tanto en oncolog\u00eda como en enfermedades inflamatorias<\/strong>.<\/p>\n

[\/vc_column_text][\/vc_column][\/vc_row][vc_row foundry_padding=\u00bbpt0″][vc_column css_animation=\u00bbfadeInLeft\u00bb][vc_column_text]<\/p>\n

Programas CCR9. Evidencia cient\u00edfica<\/h3>\n

[\/vc_column_text][\/vc_column][vc_column css_animation=\u00bbfadeInUp\u00bb el_class=\u00bblista\u00bb][vc_column_text el_class=\u00bblista\u00bb]<\/p>\n

CCR9 EN EII<\/h4>\n

[\/vc_column_text][vc_column_text]<\/p>\n

    \n
  • CCR9 dirige la migraci\u00f3n de linfocitos hacia el intestino, actuando como un regulador clave del tr\u00e1fico inmunitario intestinal.<\/li>\n
  • En la EII, la desregulaci\u00f3n del eje CCR9\/CCL25 se asocia con la inflamaci\u00f3n intestinal y la actividad de la enfermedad.<\/li>\n
  • Se ha descrito un aumento de c\u00e9lulas T CCR9\u207a en pacientes con inflamaci\u00f3n intestinal.<\/li>\n
  • SRB5<\/strong> ha sido dise\u00f1ado para eliminar selectivamente las c\u00e9lulas T patog\u00e9nicas CCR9\u207a mediante citotoxicidad celular dependiente de anticuerpos (ADCC)<\/strong>, contribuyendo a restaurar el equilibrio inmunitario en el tejido intestinal inflamado.<\/li>\n<\/ul>\n

    [\/vc_column_text][vc_single_image image=\u00bb1558″ img_size=\u00bbFULL\u00bb][vc_column_text el_class=\u00bblista\u00bb]<\/p>\n

    CCR9 EN ONCOLOG\u00cdA<\/h4>\n

    [\/vc_column_text][vc_column_text]<\/p>\n

      \n
    • La sobreexpresi\u00f3n de CCR9 est\u00e1 asociada con la progresi\u00f3n tumoral, la met\u00e1stasis y la resistencia terap\u00e9utica en tumores s\u00f3lidos como el adenocarcinoma ductal pancre\u00e1tico (PDAC), el c\u00e1ncer de ovario y el c\u00e1ncer de pulm\u00f3n.<\/li>\n
    • En tumores hematol\u00f3gicos, CCR9 se encuentra frecuentemente sobreexpresado en la leucemia linfobl\u00e1stica aguda de c\u00e9lulas T (T-ALL) y la leucemia mieloide aguda (AML), donde se relaciona con el inicio y la progresi\u00f3n de la enfermedad.<\/li>\n
    • SRB123<\/strong> ha sido dise\u00f1ado para administrar selectivamente una potente carga citot\u00f3xica a las c\u00e9lulas tumorales CCR9\u207a, induciendo una destrucci\u00f3n dirigida de las c\u00e9lulas cancerosas y minimizando la exposici\u00f3n de los tejidos CCR9 negativos.<\/li>\n<\/ul>\n

      [\/vc_column_text][vc_single_image image=\u00bb1564″ img_size=\u00bbFULL\u00bb][\/vc_column][\/vc_row][vc_row foundry_padding=\u00bbpt0 pb0″][vc_column css_animation=\u00bbfadeInLeft\u00bb][vc_column_text]<\/p>\n

      Anticuerpos terap\u00e9uticos anti-CCR9<\/h2>\n

      [\/vc_column_text][\/vc_column][vc_column css_animation=\u00bbfadeInUp\u00bb][vc_column_text]<\/p>\n

      SunRock ha desarrollado SRB5<\/strong>, un anticuerpo anti-CCR9 humanizado con actividad mejorada de citotoxicidad celular dependiente de anticuerpos (ADCC)<\/strong> para la eliminaci\u00f3n de c\u00e9lulas T CCR9\u207a en el contexto de la EII. Su eficacia ha sido demostrada in vitro, in vivo y ex vivo<\/strong> en biopsias intestinales de pacientes con EII.<\/p>\n

      SunRock tambi\u00e9n ha desarrollado SRB123<\/strong>, un conjugado anticuerpo-f\u00e1rmaco (ADC<\/strong>) anti-CCR9 pionero en su clase, dise\u00f1ado para dirigirse selectivamente a las c\u00e9lulas tumorales CCR9\u207a y eliminarlas. Conjugado a una carga citot\u00f3xica de nueva generaci\u00f3n basada en un inhibidor de la topoisomerasa I, SRB123 ha demostrado una potente y selectiva actividad citot\u00f3xica in vitro y una s\u00f3lida eficacia antitumoral in vivo en m\u00faltiples modelos precl\u00ednicos de c\u00e1ncer.<\/p>\n

      SunRock Biopharma posee los derechos exclusivos mundiales de la propiedad intelectual que protege estos anticuerpos dirigidos contra CCR9.<\/p>\n

      [\/vc_column_text][vc_tta_tour style=\u00bbflat\u00bb shape=\u00bbsquare\u00bb color=\u00bbwhite\u00bb active_section=\u00bb1″ el_class=\u00bbtour-anti\u00bb][vc_tta_section title=\u00bbSRB5″ tab_id=\u00bb1582107529302-90b36921-4902″][vc_column_text]El principal activo de SunRock, SRB5<\/strong>, es un anticuerpo anti-CCR9 de referencia (best-in-class<\/em>) cuyo mecanismo de acci\u00f3n se basa en la ADCC y que ha demostrado la eliminaci\u00f3n de c\u00e9lulas T que expresan CCR9 tanto en sangre perif\u00e9rica como en tejido intestinal, tanto in vivo<\/strong> como ex vivo<\/strong> en muestras de pacientes.[\/vc_column_text][vc_column_text el_class=\u00bblista\u00bb]<\/p>\n

      SRB5 demostr\u00f3 eficacia ex vivo en explantes intestinales de pacientes con EII<\/h4>\n
        \n
      • El tratamiento con SRB5 reduce espec\u00edficamente el porcentaje de subpoblaciones de linfocitos T CCR9\u207a en sangre perif\u00e9rica, sin afectar al n\u00famero total de linfocitos T circulantes.<\/li>\n
      • SRB5 demuestra eficacia terap\u00e9utica en pacientes con EII independientemente de su historial cl\u00ednico, mostrando resultados positivos tanto en pacientes na\u00efve como en aquellos tratados previamente con mesalazina, infliximab, ustekinumab o inhibidores de JAK.<\/li>\n
      • La eliminaci\u00f3n de c\u00e9lulas T CD4\u207a CCR9\u207a mediada por SRB5 se asocia con una reducci\u00f3n significativa de los niveles solubles de las principales citocinas proinflamatorias.<\/li>\n<\/ul>\n

        SRB5 mostr\u00f3 una uni\u00f3n, actividad ADCC y eficacia superiores a las de un anticuerpo anti-CCR9 de referencia<\/h4>\n
          \n
        • SRB5 presenta una capacidad de eliminaci\u00f3n de c\u00e9lulas T CCR9\u207a 16 veces superior<\/strong> a la observada con un anticuerpo anti-CCR9 de referencia.<\/li>\n
        • SRB5 muestra una afinidad de uni\u00f3n en el rango subnanomolar, alcanzando una ocupaci\u00f3n del receptor significativamente mayor que la del anticuerpo de referencia.<\/li>\n
        • En ensayos con muestras derivadas de pacientes, SRB5 mostr\u00f3 una mayor eficacia que el anticuerpo anti-CCR9 de referencia en la eliminaci\u00f3n de c\u00e9lulas T CD4\u207a CCR9\u207a tanto en explantes intestinales como en sangre perif\u00e9rica.<\/li>\n
        • No se observaron signos de toxicidad en ninguno de los modelos animales evaluados.<\/li>\n<\/ul>\n

          [\/vc_column_text][\/vc_tta_section][vc_tta_section title=\u00bbSRB123″ tab_id=\u00bb1777907544396-d430b87d-b17f\u00bb][vc_column_text]SunRock est\u00e1 codesarrollando SRB123<\/strong> junto con Escugen Biotechnology<\/strong>. SRB123 es un ADC dirigido contra CCR9, pionero en su clase (first-in-class<\/em>), dise\u00f1ado para ofrecer una eficacia y un perfil de seguridad optimizados.<\/p>\n

          La plataforma tecnol\u00f3gica EZWi-Fit\u00ae<\/strong> de Escugen emplea enlazadores estables y escindibles junto con una innovadora carga basada en un inhibidor de la topoisomerasa I, demostrando una excelente actividad antitumoral y un perfil de seguridad que respaldan su potencial como tratamiento de referencia en su categor\u00eda.[\/vc_column_text][vc_column_text]<\/p>\n

          Perfil de seguridad favorable de SRB123 en ratones con DAR4 y DAR8<\/h4>\n
            \n
          • \n

            Un estudio de toxicidad con dosis repetidas en ratones knock-in<\/em> para CCR9 humano (huCCR9) demostr\u00f3 que SRB123 DAR4 y DAR8 fueron bien tolerados.<\/p>\n<\/li>\n

          • \n

            No se observaron signos cl\u00ednicos de toxicidad y el peso corporal permaneci\u00f3 estable y comparable al de los animales tratados con veh\u00edculo.<\/p>\n<\/li>\n<\/ul>\n

            Eficacia de SRB123 en modelos PDX de c\u00e1ncer de ovario y p\u00e1ncreas<\/h4>\n
              \n
            • \n

              SRB123 indujo una regresi\u00f3n tumoral completa en un modelo PDX altamente agresivo de carcinoma seroso de alto grado de ovario (HGSOC), derivado de organoides obtenidos a partir de l\u00edquido asc\u00edtico de una paciente con enfermedad en estadio IVB, refractaria al tratamiento con carboplatino\/paclitaxel y con r\u00e1pida progresi\u00f3n de la enfermedad.<\/p>\n<\/li>\n

            • \n

              En modelos PDX de c\u00e1ncer de p\u00e1ncreas, SRB123 logr\u00f3 estabilizaci\u00f3n tumoral en un modelo multirresistente y refractario a gemcitabina\/Abraxane\u00ae, as\u00ed como regresi\u00f3n tumoral en un segundo modelo, mostrando una clara superioridad frente al tratamiento con gemcitabina\/Abraxane\u00ae.<\/p>\n<\/li>\n<\/ul>\n

              [\/vc_column_text][\/vc_tta_section][\/vc_tta_tour][\/vc_column][\/vc_row][vc_row css_animation=\u00bbfadeInUp\u00bb el_class=\u00bbfirst-section\u00bb][vc_column el_class=\u00bbbox-shadow\u00bb][vc_column_text]<\/p>\n

              Anti-CCR9 Pipeline <\/span><\/h2>\n

              [\/vc_column_text][vc_row_inner][vc_column_inner width=\u00bb1\/6″][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom\u00bb width=\u00bb1\/6″][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom\u00bb width=\u00bb1\/12″][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom\u00bb width=\u00bb1\/12″][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom\u00bb width=\u00bb1\/12″][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom\u00bb width=\u00bb1\/12″][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom\u00bb width=\u00bb1\/12″][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom\u00bb width=\u00bb1\/12″][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner width=\u00bb1\/6″][vc_empty_space height=\u00bb65px\u00bb][vc_empty_space height=\u00bb20px\u00bb][vc_column_text]<\/p>\n

              SRB5<\/h5>\n

              [\/vc_column_text][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom\u00bb width=\u00bb1\/6″][vc_column_text]Descubrimiento<\/strong>[\/vc_column_text][vc_separator border_width=\u00bb4″][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22Discovery%22%2C%22value%22%3A%22100%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#ffce1c\u00bb][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom\u00bb width=\u00bb1\/12″][vc_empty_space height=\u00bb59px\u00bb][vc_separator color=\u00bbcustom\u00bb border_width=\u00bb4″ accent_color=\u00bb#45509a\u00bb][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22in%20vitro%22%2C%22value%22%3A%22100%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#ffce1c\u00bb el_class=\u00bbem\u00bb][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom\u00bb width=\u00bb1\/12″][vc_column_text]Precl\u00ednica<\/strong>[\/vc_column_text][vc_separator color=\u00bbcustom\u00bb border_width=\u00bb4″ accent_color=\u00bb#45509a\u00bb][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22in%20vivo%22%2C%22value%22%3A%22100%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#ffce1c\u00bb el_class=\u00bbem\u00bb][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom\u00bb width=\u00bb1\/12″][vc_empty_space height=\u00bb59px\u00bb][vc_separator color=\u00bbcustom\u00bb border_width=\u00bb4″ accent_color=\u00bb#45509a\u00bb][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22Regulatory%22%2C%22value%22%3A%2250%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#ffce1c\u00bb][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom\u00bb width=\u00bb1\/12″][vc_empty_space height=\u00bb59px\u00bb][vc_separator color=\u00bbcustom\u00bb border_width=\u00bb4″ accent_color=\u00bb#e0bf3d\u00bb][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22Phase%20I%22%2C%22value%22%3A%220%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#ffce1c\u00bb][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom\u00bb width=\u00bb1\/12″][vc_column_text]Fases cl\u00ednicas<\/strong>[\/vc_column_text][vc_separator color=\u00bbcustom\u00bb border_width=\u00bb4″ accent_color=\u00bb#e0bf3d\u00bb][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22Phase%20II%22%2C%22value%22%3A%220%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#ffce1c\u00bb][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom\u00bb width=\u00bb1\/12″][vc_empty_space height=\u00bb59px\u00bb][vc_separator color=\u00bbcustom\u00bb border_width=\u00bb4″ accent_color=\u00bb#e0bf3d\u00bb][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22Phase%20III%22%2C%22value%22%3A%220%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#ffce1c\u00bb][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner width=\u00bb1\/6″][vc_column_text]<\/p>\n

              SRB123<\/h5>\n

              [\/vc_column_text][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom\u00bb width=\u00bb1\/6″][vc_column_text el_class=\u00bbvisible-xs visible-sm\u00bb]Discovery<\/strong>[\/vc_column_text][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22Discovery%22%2C%22value%22%3A%22100%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#ffce1c\u00bb][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom\u00bb width=\u00bb1\/12″][vc_column_text el_class=\u00bbvisible-xs visible-sm\u00bb]Preclinical<\/strong>[\/vc_column_text][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22in%20vitro%22%2C%22value%22%3A%22100%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#ffce1c\u00bb el_class=\u00bbem\u00bb][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom\u00bb width=\u00bb1\/12″][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22in%20vivo%22%2C%22value%22%3A%22100%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#ffce1c\u00bb el_class=\u00bbem\u00bb][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom\u00bb width=\u00bb1\/12″][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22Regulatory%22%2C%22value%22%3A%220%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#ffce1c\u00bb][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom\u00bb width=\u00bb1\/12″][vc_column_text el_class=\u00bbvisible-xs visible-sm\u00bb]Clinic phases<\/strong>[\/vc_column_text][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22Phase%20I%22%2C%22value%22%3A%220%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#ffce1c\u00bb][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom\u00bb width=\u00bb1\/12″][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22Phase%20II%22%2C%22value%22%3A%220%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#ffce1c\u00bb][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom\u00bb width=\u00bb1\/12″][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22Phase%20III%22%2C%22value%22%3A%220%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#ffce1c\u00bb][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row]<\/p>\n","protected":false},"excerpt":{"rendered":"

              [vc_row][vc_column css_animation=\u00bbfadeInUp\u00bb el_class=\u00bbbox-shadow\u00bb][vc_column_text] CCR9 como diana terap\u00e9utica [\/vc_column_text][vc_column_text] El receptor de quimiocinas 9 (CCR9) es un receptor acoplado a prote\u00edna G…<\/p>\n","protected":false},"author":1,"featured_media":573,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_mi_skip_tracking":false,"footnotes":""},"class_list":["post-1618","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"\r\nSunRock Biopharma | CCR9<\/title>\r\n<meta name=\"description\" content=\"CCR9 means Chemotactic cytokine Receptor 9. Chemotactic cytokines or Chemokines bind to G protein-coupled receptors and mediate a wide range of biological functions, among them leukocyte adhesion and extravasation.\" \/>\r\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\r\n<link rel=\"canonical\" href=\"https:\/\/www.sunrockbiopharma.com\/es\/ccr9\/\" \/>\r\n<meta property=\"og:locale\" content=\"es_ES\" \/>\r\n<meta property=\"og:type\" content=\"article\" \/>\r\n<meta property=\"og:title\" content=\"SunRock Biopharma | CCR9\" \/>\r\n<meta property=\"og:description\" content=\"CCR9 means Chemotactic cytokine Receptor 9. Chemotactic cytokines or Chemokines bind to G protein-coupled receptors and mediate a wide range of biological functions, among them leukocyte adhesion and extravasation.\" \/>\r\n<meta property=\"og:url\" content=\"https:\/\/www.sunrockbiopharma.com\/es\/ccr9\/\" \/>\r\n<meta property=\"og:site_name\" content=\"SunRock Biopharma\" \/>\r\n<meta property=\"article:modified_time\" content=\"2026-06-23T09:15:54+00:00\" \/>\r\n<meta property=\"og:image\" content=\"https:\/\/www.sunrockbiopharma.com\/wp-content\/uploads\/2020\/09\/sunrock-seo-fb.png\" \/>\r\n\t<meta property=\"og:image:width\" content=\"1201\" \/>\r\n\t<meta property=\"og:image:height\" content=\"631\" \/>\r\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\r\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\r\n<meta name=\"twitter:title\" content=\"SunRock Biopharma | CCR9\" \/>\r\n<meta name=\"twitter:description\" content=\"CCR9 means Chemotactic cytokine Receptor 9. Chemotactic cytokines or Chemokines bind to G protein-coupled receptors and mediate a wide range of biological functions, among them leukocyte adhesion and extravasation.\" \/>\r\n<meta name=\"twitter:image\" content=\"https:\/\/www.sunrockbiopharma.com\/wp-content\/uploads\/2020\/09\/sunrock-seo-tw.png\" \/>\r\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"6 minutos\" \/>\r\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.sunrockbiopharma.com\\\/es\\\/ccr9\\\/\",\"url\":\"https:\\\/\\\/www.sunrockbiopharma.com\\\/es\\\/ccr9\\\/\",\"name\":\"SunRock Biopharma | CCR9\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.sunrockbiopharma.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.sunrockbiopharma.com\\\/es\\\/ccr9\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sunrockbiopharma.com\\\/es\\\/ccr9\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.sunrockbiopharma.com\\\/wp-content\\\/uploads\\\/2020\\\/02\\\/83159984_l-scaled.jpg\",\"datePublished\":\"2026-05-08T11:53:38+00:00\",\"dateModified\":\"2026-06-23T09:15:54+00:00\",\"description\":\"CCR9 means Chemotactic cytokine Receptor 9. Chemotactic cytokines or Chemokines bind to G protein-coupled receptors and mediate a wide range of biological functions, among them leukocyte adhesion and extravasation.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.sunrockbiopharma.com\\\/es\\\/ccr9\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.sunrockbiopharma.com\\\/es\\\/ccr9\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/www.sunrockbiopharma.com\\\/es\\\/ccr9\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.sunrockbiopharma.com\\\/wp-content\\\/uploads\\\/2020\\\/02\\\/83159984_l-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/www.sunrockbiopharma.com\\\/wp-content\\\/uploads\\\/2020\\\/02\\\/83159984_l-scaled.jpg\",\"width\":2560,\"height\":1792,\"caption\":\"Laboratory.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.sunrockbiopharma.com\\\/es\\\/ccr9\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.sunrockbiopharma.com\\\/es\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CCR9\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.sunrockbiopharma.com\\\/#website\",\"url\":\"https:\\\/\\\/www.sunrockbiopharma.com\\\/\",\"name\":\"SunRock Biopharma\",\"description\":\"Next-Generation Antibodies\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.sunrockbiopharma.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.sunrockbiopharma.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.sunrockbiopharma.com\\\/#organization\",\"name\":\"SunRock Biopharma\",\"url\":\"https:\\\/\\\/www.sunrockbiopharma.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/www.sunrockbiopharma.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.sunrockbiopharma.com\\\/wp-content\\\/uploads\\\/2020\\\/09\\\/sunrock-seo-fb.png\",\"contentUrl\":\"https:\\\/\\\/www.sunrockbiopharma.com\\\/wp-content\\\/uploads\\\/2020\\\/09\\\/sunrock-seo-fb.png\",\"width\":1201,\"height\":631,\"caption\":\"SunRock Biopharma\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sunrockbiopharma.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\r\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SunRock Biopharma | CCR9","description":"CCR9 means Chemotactic cytokine Receptor 9. Chemotactic cytokines or Chemokines bind to G protein-coupled receptors and mediate a wide range of biological functions, among them leukocyte adhesion and extravasation.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.sunrockbiopharma.com\/es\/ccr9\/","og_locale":"es_ES","og_type":"article","og_title":"SunRock Biopharma | CCR9","og_description":"CCR9 means Chemotactic cytokine Receptor 9. Chemotactic cytokines or Chemokines bind to G protein-coupled receptors and mediate a wide range of biological functions, among them leukocyte adhesion and extravasation.","og_url":"https:\/\/www.sunrockbiopharma.com\/es\/ccr9\/","og_site_name":"SunRock Biopharma","article_modified_time":"2026-06-23T09:15:54+00:00","og_image":[{"width":1201,"height":631,"url":"https:\/\/www.sunrockbiopharma.com\/wp-content\/uploads\/2020\/09\/sunrock-seo-fb.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_title":"SunRock Biopharma | CCR9","twitter_description":"CCR9 means Chemotactic cytokine Receptor 9. Chemotactic cytokines or Chemokines bind to G protein-coupled receptors and mediate a wide range of biological functions, among them leukocyte adhesion and extravasation.","twitter_image":"https:\/\/www.sunrockbiopharma.com\/wp-content\/uploads\/2020\/09\/sunrock-seo-tw.png","twitter_misc":{"Tiempo de lectura":"6 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.sunrockbiopharma.com\/es\/ccr9\/","url":"https:\/\/www.sunrockbiopharma.com\/es\/ccr9\/","name":"SunRock Biopharma | CCR9","isPartOf":{"@id":"https:\/\/www.sunrockbiopharma.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.sunrockbiopharma.com\/es\/ccr9\/#primaryimage"},"image":{"@id":"https:\/\/www.sunrockbiopharma.com\/es\/ccr9\/#primaryimage"},"thumbnailUrl":"https:\/\/www.sunrockbiopharma.com\/wp-content\/uploads\/2020\/02\/83159984_l-scaled.jpg","datePublished":"2026-05-08T11:53:38+00:00","dateModified":"2026-06-23T09:15:54+00:00","description":"CCR9 means Chemotactic cytokine Receptor 9. Chemotactic cytokines or Chemokines bind to G protein-coupled receptors and mediate a wide range of biological functions, among them leukocyte adhesion and extravasation.","breadcrumb":{"@id":"https:\/\/www.sunrockbiopharma.com\/es\/ccr9\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sunrockbiopharma.com\/es\/ccr9\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.sunrockbiopharma.com\/es\/ccr9\/#primaryimage","url":"https:\/\/www.sunrockbiopharma.com\/wp-content\/uploads\/2020\/02\/83159984_l-scaled.jpg","contentUrl":"https:\/\/www.sunrockbiopharma.com\/wp-content\/uploads\/2020\/02\/83159984_l-scaled.jpg","width":2560,"height":1792,"caption":"Laboratory."},{"@type":"BreadcrumbList","@id":"https:\/\/www.sunrockbiopharma.com\/es\/ccr9\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.sunrockbiopharma.com\/es\/home\/"},{"@type":"ListItem","position":2,"name":"CCR9"}]},{"@type":"WebSite","@id":"https:\/\/www.sunrockbiopharma.com\/#website","url":"https:\/\/www.sunrockbiopharma.com\/","name":"SunRock Biopharma","description":"Next-Generation Antibodies","publisher":{"@id":"https:\/\/www.sunrockbiopharma.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sunrockbiopharma.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.sunrockbiopharma.com\/#organization","name":"SunRock Biopharma","url":"https:\/\/www.sunrockbiopharma.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.sunrockbiopharma.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.sunrockbiopharma.com\/wp-content\/uploads\/2020\/09\/sunrock-seo-fb.png","contentUrl":"https:\/\/www.sunrockbiopharma.com\/wp-content\/uploads\/2020\/09\/sunrock-seo-fb.png","width":1201,"height":631,"caption":"SunRock Biopharma"},"image":{"@id":"https:\/\/www.sunrockbiopharma.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.sunrockbiopharma.com\/es\/wp-json\/wp\/v2\/pages\/1618","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sunrockbiopharma.com\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.sunrockbiopharma.com\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.sunrockbiopharma.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.sunrockbiopharma.com\/es\/wp-json\/wp\/v2\/comments?post=1618"}],"version-history":[{"count":3,"href":"https:\/\/www.sunrockbiopharma.com\/es\/wp-json\/wp\/v2\/pages\/1618\/revisions"}],"predecessor-version":[{"id":1621,"href":"https:\/\/www.sunrockbiopharma.com\/es\/wp-json\/wp\/v2\/pages\/1618\/revisions\/1621"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.sunrockbiopharma.com\/es\/wp-json\/wp\/v2\/media\/573"}],"wp:attachment":[{"href":"https:\/\/www.sunrockbiopharma.com\/es\/wp-json\/wp\/v2\/media?parent=1618"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}